DZD8586 for Non-Hodgkin's Lymphoma

Recruiting at 5 trial locations

Overseen By Ziyi Liu

Age: 18+

Sex: Any

Trial Phase: Phase 1

Sponsor: Dizal Pharmaceuticals

Must not be taking: Corticosteroids, Immunosuppressives

Disqualifiers: Stroke, Cardiac disorders, Other malignancy, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

Duration: 8-12 weeks

230 Participants Needed

Trial Summary

Will I have to stop taking my current medications?

The trial protocol does not specify if you need to stop taking your current medications. However, it mentions that certain therapies and treatments must be stopped for specific periods before starting the trial, such as small molecule therapies and monoclonal antibodies. It's best to discuss your current medications with the trial team.

What is the purpose of this trial?

This study will treat patients with B-NHL who have relapsed, progressed, or were intolerant to systemic therapy progressed following prior therapy. This study will help to understand what type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and assess its anti-cancer activity as monotherapy.

Research Team

Tianwei Zhang

Principal Investigator

Dizal Pharma

Eligibility Criteria

This trial is for adults over 18 with B-cell Non-Hodgkin Lymphoma (B-NHL) that has come back or didn't respond to previous treatments. They should be relatively active and stable in the last two weeks, have good bone marrow and organ function, and agree to follow birth control rules during the study.

Inclusion Criteria

I can care for myself and my physical condition hasn't worsened in the last 2 weeks.

I am willing to follow the study's birth control requirements.

My B-cell lymphoma diagnosis is confirmed by lab tests.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive DZD8586 to evaluate safety, tolerability, pharmacokinetics, and anti-tumor efficacy

8-12 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

• DZD8586

Trial Overview The trial is testing DZD8586 as a single therapy on patients with B-NHL who haven't had success with other treatments. It aims to understand side effects, how much of the drug stays in the body, and its effectiveness against cancer.

Participant Groups

Group I: DZD8586 Experimental Treatment 1 Intervention

Who Is Running the Clinical Trial?

Dizal Pharmaceuticals

Lead Sponsor

Trials

27

Recruited

2,500+